Alto Neuroscience

Advancing the most robust #PrecisionPsychiatry pipeline to bring every person suffering from a mental health condition the right treatment, right away.

[Alto Neuroscience @AltoNeuro]

@AltoNeuro is excited to participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (Hybrid). Hear from our leadership team on our mission to redefine psychiatry with personalized precision medicines.

Learn more here: https://t.co/Sz3I2DHiKc

#Biotech

[Alto Neuroscience @AltoNeuro]

Ph2 findings for ALTO-203 showed improvements in attention, alertness, & EEG biomarkers in patients with depression. In a recent @PsychTimes interview, Amit Etkin, MD, PhD, discusses how these findings may help identify patients most likely to benefit.

https://t.co/6yqA3Ze4jv

[Alto Neuroscience @AltoNeuro]

We’re excited to announce the appointment of Andrew Miller, Ph.D., to @AltoNeuro Board of Directors, effective May 27, 2026.

Andrew brings extensive leadership experience across neuroscience, biotechnology, & precision medicine.

https://t.co/tkrwr25nLz

[Alto Neuroscience @AltoNeuro]

@AltoNeuro Founder & CEO Amit Etkin, M.D., Ph.D., has received the Transformational Research Award from Columbia University VP&S Alumni Association, recognizing his leadership in advancing precision psychiatry and biomarker-based innovation.

Full video: https://t.co/rzF1nMDPdF

[Alto Neuroscience @AltoNeuro]

Today, @AltoNeuro reported first quarter 2026 financial results and recent business highlights.

Learn more here: https://t.co/aasUyRcttO

[Alto Neuroscience @AltoNeuro]

@AltoNeuro is heading to @BofA_News Healthcare Conference and @Jefferies Global Healthcare Conference.

Hear from our leadership team as we advance our robust clinical-stage pipeline across mental health conditions.

Learn more: https://t.co/hJQPwFsN7U

#PrecisionPsychiatry

[Alto Neuroscience @AltoNeuro]

At #SOBP2026, @AltoNeuro presented Phase 2a data for ALTO-207 in MDD.

Statistically significant antidepressant effects and favorable tolerability support ongoing Phase 2b development in TRD.

Read more here: https://t.co/16ZsQR4zy5

#Neuroscience #Neuroscience

[Alto Neuroscience @AltoNeuro]

@AltoNeuro launches Phase 2b trial of ALTO-207 in treatment-resistant depression.

· Built on strong PAX-D efficacy signal
· Designed for improved tolerability
· Registrationally aligned study

Data expected 2H 2027.  Read more: https://t.co/SWv0OYXPBW

[Alto Neuroscience @AltoNeuro]

Our CEO, Dr. @AmitEtkin, joined The BioHub Podcast to discuss precision psychiatry and moving beyond trial-and-error treatment in mental health.

Listen on Spotify, Apple Podcasts, or LinkedIn.
https://t.co/QniPvu2Sqa

#Neuroscience #MentalHealth #HealthcareInnovation

[Alto Neuroscience @AltoNeuro]

Today, @AltoNeuro reported full-year 2025 financial results and recent business highlights.

Learn more about our pipeline and upcoming milestones here: https://t.co/lSXY0PcxOk

[Alto Neuroscience @AltoNeuro]

@AltoNeuro is excited to present at the Stifel 2026 Virtual CNS Forum - hear from our leadership team on March 17th at 12pm ET about our mission to redefine psychiatry with precision medicine.

Learn more here: https://t.co/UHZeApJicC

#PrecisionPsychiatry #StifelCNS

[Alto Neuroscience @AltoNeuro]

Alto Neuroscience is heading to TD Cowen and Jefferies Biotech on the Beach this month!

Hear from our leadership team on our mission to redefine psychiatry with personalized precision medicines.

Learn more: https://t.co/EhsPp9qs4k

#AltoNeuroscience #PrecisionPsychiatry

[Alto Neuroscience @AltoNeuro]

Our CEO, Dr. @AmitEtkin, joined @thehctheory to discuss precision psychiatry and moving beyond trial-and-error treatment in mental health.

Listen on #Spotify, #ApplePodcasts, or #thehctheory website. https://t.co/WtyvI0zaHc

#Neuroscience #MentalHealth #HealthcareInnovation

[Alto Neuroscience @AltoNeuro]

New publication in the American Journal of Psychiatry: @AltoNeuro highlights neuroplasticity as a core, druggable driver of psychiatric disease, reinforcing the scientific foundation of our precision psychiatry platform.

https://t.co/zKBRViyX4Y

#Neuroscience #MentalHealth

[Alto Neuroscience @AltoNeuro]

#ICYMI: New data from @AltoNeuro at ACNP 2026 underscore the strength of our precision platform and advancing clinical pipeline.

Details: https://t.co/MBLsm9danH

[Alto Neuroscience @AltoNeuro]

At #JPMWeek, our CEO @AmitEtkin sat down with @JonahComstock, Editor-in-Chief of @pharmaphorum, to discuss @AltoNeuro's biology-driven approach and what’s ahead in schizophrenia, depression, and bipolar disorder.

🎥 Full interview: https://t.co/u1BmWkDz1d

#Neuroscience

[Alto Neuroscience @AltoNeuro]

@AltoNeuro announced a new U.S. method-of-treatment patent for ALTO-207 in depression, strengthening protection for this differentiated program in treatment-resistant patients.

https://t.co/kYZA04dHwb

#PrecisionPsychiatry #Depression #Neuroscience #Biotech

[Alto Neuroscience @AltoNeuro]

Today, @AltoNeuro reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.

Learn more here: https://t.co/6QuulRXELs

[Alto Neuroscience @AltoNeuro]

A proud day for Alto Neuroscience at the @NYSE.

We rang the Opening Bell today to celebrate our ongoing commitment to transforming the treatment of mental health disorders through precision psychiatry.

[Alto Neuroscience @AltoNeuro]

Excited to join the conversation at upcoming investor conferences!

Stifel 2025 Healthcare Conf. – Nov 12, 10:00 AM ET, NYC
Jefferies London Healthcare Conf. – Nov 17, 3:30 PM GMT

Webcasts: https://t.co/MVtvgkDlIA
Read more here: https://t.co/CqbBqmhzFw

#Biotech #Neuroscience